Matching articles for "Vaxneuvance"
Issue 1734 · August 4, 2025 Free
Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old (online only)

View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old

Med Lett Drugs Ther. 2025 Aug 4; 67(1734):e1 doi:10.58347/tml.2025.1734f
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old
Issue 1734 · August 4, 2025 Free
Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old (online only)

View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old

Med Lett Drugs Ther. 2025 Aug 4; 67(1734):e1 doi:10.58347/tml.2025.1734g
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old
Issue 1713 · October 14, 2024 Free
Capvaxive – A 21-Valent Pneumococcal Conjugate Vaccine

The FDA has licensed Capvaxive (PCV21; Merck), a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia in adults. Four other pneumococcal…

Med Lett Drugs Ther. 2024 Oct 14; 66(1713):161-3 doi:10.58347/tml.2024.1713a
The FDA has licensed Capvaxive (PCV21; Merck), a 21-valent pneumococcal conjugate vaccine, for prevention of invasive pneumococcal disease (IPD) and pneumococcal pneumonia in adults. Four other pneumococcal vaccines are currently available in the US: Prevnar 20 (PCV20), Vaxneuvance (PCV15), and Prevnar 13 (PCV13) are conjugate vaccines licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23) is a pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years old (see Table 1).
Issue 1661 · October 17, 2022
Adult Immunization

The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these…

Med Lett Drugs Ther. 2022 Oct 17; 64(1661):161-8
The Advisory Committee on Immunization Practices (ACIP) recommends use of certain vaccines in adults residing in the US. Routine childhood immunization has reduced the overall incidence of some of these vaccine-preventable diseases, but many adults remain susceptible. Recommendations for vaccination against COVID-19, seasonal influenza, and monkeypox and vaccination of travelers have been reviewed separately.
Issue 1661 · October 17, 2022 Free
Expanded Table: Some Vaccines for Adults (online only)
Med Lett Drugs Ther. 2022 Oct 17; 64(1661):e170-3
Issue 1638 · November 29, 2021
Two New Pneumococcal Vaccines - Prevnar 20 and Vaxneuvance

The FDA has licensed two new pneumococcal conjugate vaccines (PCVs) for prevention of invasive pneumococcal disease in adults: Prevnar 20 (PCV20; Pfizer), which contains antigens from 20 serotypes of…

Med Lett Drugs Ther. 2021 Nov 29; 63(1638):188-90
The FDA has licensed two new pneumococcal conjugate vaccines (PCVs) for prevention of invasive pneumococcal disease in adults: Prevnar 20 (PCV20; Pfizer), which contains antigens from 20 serotypes of pneumococcus, and Vaxneuvance (PCV15; Merck), which contains antigens from 15 serotypes. Two other pneumococcal vaccines are available in the US: Prevnar 13 (PCV13; Pfizer), a 13-valent conjugate vaccine licensed for use in persons ≥6 weeks old, and Pneumovax 23 (PPSV23; Merck), a 23-valent pneumococcal polysaccharide vaccine licensed for use in persons ≥2 years old.